

Haematological evaluation of *Cryptolepis sanguinolenta* stem ethanolic extract in rats

Ajayi A.F^{1*}, Akhigbe R.E¹, Adewumi O.M², Olaleye S.B³

¹Department of Physiology, College of Health Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo state, Nigeria. ²Department of Plant Biology, Faculty of Sciences, University of Ilorin, Ilorin, Kwara state, Nigeria. ³Department of Physiology, College of Medicine, University of Ibadan, Ibadan, Oyo state, Nigeria.

*Corresponding Author: jy_ayodeji@yahoo.com

ABSTRACT

Background: The use of *Cryptolepis sanguinolenta* extract in medicare has gained attention since its discovery. **Aim:** This study sought to evaluate the haematological effect of ethanolic extract of *Cryptolepis sanguinolenta* stem in rat model. **Materials and Methods:** Control rats received 0.5ml of distilled water. Treated rats were administered oral doses of the extract at different concentrations (50, 150, and 250mg/kg body weight). All rats were maintained on a control diet. Treatment lasted for 21 days. **Results:** Red blood cells and haematological parameters were comparable in all groups. Similarly, total white blood cells, neutrophils and lymphocytes counts were not significantly altered except in rats treated with 250mg/kg/bw of the extract. However, administration of the extract led to a dose-dependent rise in platelet counts. **Conclusion:** This study showed that *C. sanguinolenta* stem ethanolic extract presents haematological challenges on white blood cells and platelets. It showed localized systemic toxicity by selectively stimulating the bone marrow.

Key words: *Cryptolepis sanguinolenta*, red blood cell, white blood cell, platelet, toxicity

INTRODUCTION

Complementary and alternative medicine has been from time immemorial. It involves the use of plants and their products for treatment of ailment. Herbal medicine plays a major role in the health of millions of people worldwide.^[1] Though, it is not considered as an integral part of orthodox medicine,^[2] which has grown to be sophisticated over years,^[3] a chunk of the drugs used in orthodox medicine are from plants and their bioactive principles extracted from them. Though the desire for a more Western lifestyle and other factors promoting globalization has influenced the use of herbal remedies,^[1] they

remain easily and cheaply available options. An elaborate plant knowledge-base is found in Africa^[4] and other parts of the globe, which has been transferred within the family unit or community^[5] from one generation to another, however, the search for more plants of medicinal value should be encouraged to provide cheaper and safer alternatives.

Cryptolepis sanguinolenta is one of the plants that have gained more attention since its discovery and isolation of the major active alkaloid in Nigeria and subsequently Ghana.^[6,7] It is a thin-stemmed twining and scrambling shrub.^[8] The leaves are

petiolate, glabrous or elliptic and are about 7cm long and 3cm wide. The roots are yellowish brown on the outer surface with a faint odour and a bitter taste.^[8] *C. sanguinolenta* has been reported to have various therapeutic values including antimalarial,^[9-13] antidiabetic,^[14-17] anticancer,^[18] antithrombotic,^[19] antimicrobial,^[20-26] and anti-inflammatory.^[27,28] The biological activities of *C. sanguinolenta* have been ascribed to its alkaloid constituents, mainly cryptolepine, indoquinoline alkaloids.^[29-34]

Although the medicinal values of *C. sanguinolenta* extract in the management of various pathologic conditions have been well documented, it is necessary to evaluate its toxic effect. The present study thus sought to investigate the potential haematotoxicity of *C. sanguinolenta* stem ethanolic extract.

METHODS AND MATERIALS

Plant material

Cryptolepis sanguinolenta stem were obtained from Ojurin Akobo- Olorunda road, Oyo, Oyo state, Nigeria. The plant was authenticated by Ugboju A, Chukwuma E.C, and Shasanya O.S of the Forest Herbarium, Ibadan, Nigeria, where a voucher specimen (FHI. 108847) has been deposited. The dried stem was broken into pieces and beaten into smaller sizes using mortar and pestle before being pulverized. The powder formed after pulverization was weighed and stored until required.^[14]

Preparation of *Cryptolepis sanguinolenta* stems ethanolic extract

Extract was prepared as described by previous studies.^[14,35] Briefly, 1,226g of the powdery stem was dissolved in 4.8 litres of 65% ethanol. The mixture was dissolved to stand for 48 hours. The extract was thereafter filtered using clothen sieve and was evaporated at 40°C. From the viscous solution obtained, a 0.1M solution of extract was prepared by dissolving 5ml of viscous solution of extract in 45ml of distilled water.

Acclimatization

Albino rats (*Rattus norvegicus*) of both sexes and comparable weights were obtained from the Animal Holding Unit of the department. The rats were housed in clean standard plastic cages in a well-ventilated laboratory condition (12:12h light/dark cycle at 25°C ± 2). The animals were allowed free access to standard rat chow and water.^[36]

Animal grouping and extract administration

After two weeks of acclimatization, the rats (24) were randomized completely into four groups of 6 each and were orally administered as follows using an oropharyngeal cannula. Doses are as used in our previous study.^[14] The control was administered 0.5ml of distilled water while groups 1, 2 and 3 were given equal doses of the extract corresponding to 50, 150 and 250mg/kg body weight respectively. Rats were sacrificed 24hr after the 21st day of treatment. Animals received humane care as recommended by the institution's guideline and criteria for humane care as stated in the National Institute of Health Guidelines for the Care and Use of Laboratory Animals.

Serum preparation and determination of haematological parameters

Serum was prepared accordingly to previously established procedure of Yakubu *et al.*^[37,38] Briefly, the cervical region of the rats was shaved to reveal the jugular veins under ether anaesthesia. The veins were slightly displaced to prevent blood contamination by interstitial fluid, and sharply cut with sterile surgical blade. Blood samples were collected in lithium-heparinized sample bottles for haematological analysis.

Haematological parameters were evaluated as described in previous studies^[39-43] using standard laboratory assay kits in accordance to manufacturer's instruction.

Statistical analysis

Data were subjected to analysis of variance (ANOVA) and unpaired t-test. Data were expressed as mean±standard error of mean. Significant levels were tested at $p < 0.05$.

RESULTS

Though ethanolic extract of *C. sanguinolenta* stem caused marginal fluctuations of red blood cells (RBC), packed cell volume (PCV), haemoglobin (Hb), mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC), these alterations were not statistically significant. In contrast, the extract led to a dose-dependent increase in platelet count.

Total white blood cell (TWBC), neutrophils and lymphocytes were comparable in the control and groups treated with 50 and 150mg/kgBW of the extract. However, these white cell variables were

significantly increased in rats treated with 250mg/kg/bw of the extract.





DISCUSSION

Haematological indices provide physiological information on the blood picture and the reticuloendothelial system,^[44] thus are used in the diagnosis of diseases^[45] and evaluation of the toxic effects of exogenous compounds including plant extracts and drugs. Haematological analysis is consequently relevant to toxicity evaluation as haematological changes have higher predictive value for human toxicity when the data are interpreted from animal studies.^[46]

The results from this study revealed that *C. sanguinolenta* did not alter red blood cells and its related indices. This may also show that the extract did not stimulate the humoral regulator of RBC production, erythropoietin.^[38,47] RBC, PCV and Hb are associated with the total population of the red cells, while MCV, MCH, and MCHC are related to individual RBC. The non-toxic effect of the extract on these parameters suggests that it does not modulate the incorporation of haemoglobin into the red cells nor alter the morphology and osmotic fragility of the red blood stem cells.^[48] These observations also imply that the extract does not affect the oxygen-carrying capacity of the red cells, implying that the botanical does not possess anaemic potential.

It is striking that though *C. sanguinolenta* did not alter red cells and its related indices, white cells and related indices were significantly increased in rats treated with 250mg/kgBW. The rise in TWBC may be due to enhancement of white cell production, increase in its entrance into the blood, and a reduction in its removal from the circulation.^[38] This may indicate that the extract led to hyperstimulation of haematopoietic regulatory elements by the macrophages and stromal cells in the bone marrow such as colony stimulating factors, interleukins (IL-2, IL-4 and IL-5) which regulate the proliferation, differentiation and maturation of committed stem cells necessary for the production of white blood cells.

White cells and its indices play a vital immune function. Neutrophils have phagocytic activities.^[42] They attack and destroy foreign particles, cell waste materials and bacteria. The lymphocytes help to specifically recognize a diverse range of antigens, differentiate and mature to functional capacity, respond to the antigens and establish immunologic memory.^[49-52] The increased neutrophils and lymphocytes seen in the study showed that the



extract at 250mg/kg/bw boosted the immune system.

Results from this study also showed that *C. sanguinolenta* caused an increase in platelets (thrombocytes) in a dose-dependent fashion. Platelets are responsible for coagulation.^[53] The rise in platelets count seen in the present study may suggest that the extract has a stimulatory effect on thrombopoietin,^[54] an important factor in thrombopoiesis.

The blood cells are produced mainly in the bone marrow.^[55,56] The rise in white cells and platelets accompanied with normal red cell counts suggest a selective stimulatory effect of *C. sanguinolenta* on the bone marrow.^[38] This may infer a localized systemic toxicity of the botanical. This is in consonance with previous findings^[48] that documented selective stimulatory effects of different botanicals on the bone marrow.

CONCLUSION

This study showed that *C. sanguinolenta* stem ethanolic extract poses haematological challenges on white blood cells and platelets. It showed localized systemic toxicity by selectively stimulating the bone marrow.

REFERENCES

1. Harun-Or-Rashid, Yoshida, Aminur Rashid Md., Nahar Salmun, and Sakamoto Junichi. Perceptions of the Muslim Religious Leaders and their attitudes on Herbal Medicine in Bangladesh: A Cross-sectional study. *BMC Research Notes* 2011;4:366-395.
2. Ezeome ER, Anarado AN. Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. *BMC Complement Altern Med* 2007;7:28.
3. Erah PO. Herbal Medicines: Challenges [Editorial]. *Trop J Pharm Res* 2002;2:53-54
4. Barrow EGC. The dry lands of Africa: Local participation in tree management. Nairobi, Initiative, Publishers 1996.
5. Fratkin EM. Traditional medicine and concepts of healing among Samburu pastoralists of Kenya. *Journal of Ethnobiology* 1996;1:63-97.
6. Gellert E, Raymond-Hamet, Schlittler E. Die Konstitution des Alkaloids Cryptolepin. (The structure of the alkaloid cryptolepine) *Helv Chim Acta* 1951;34:642-51.
7. Dwuma-Badu D, Ayim JSK, Fiagbe NYI, Knapp PhE, Schiff Jr. PL, Slatkin DJ. Constituents of West African medicinal plants XX: Quindoline from *Cryptolepis sanguinolenta*. *J Pharm Sci* 1978;67:4339-434.
8. Mshana NR, Abbiw DK, Addaeh-Mensah E, Ahiyi MRA and Ekpera JA. Traditional medicine and pharmacopoeia. Contribution to the Revision of Ethnobotanical and Floristic Studies in Ghana Organization of African Unity/ Scientific, Technical and Research Committee. 2000, pp 473.
9. Bugyei KA, Boye GL, and Addy ME. Clinical Efficacy of a Tea-Bag Formulation of *Cryptolepis Sanguinolenta* Root in the Treatment of Acute Uncomplicated Falciparum Malaria. *Ghana Med J* 2010;44: 3-9.
10. Wright CW, Phillipson JD, Awe SO, Kirby GC, Warhurst DC, Quertin-Leclercq J, Angenot L. Antimalarial activity of cryptolepine and some other anhydronium bases. *Phytother Res* 1996;10:361-363.
11. Grellier P, Ramiaramanana L, Milleriox V, Deharo E, Shrevel J, Frappier F. Antimalarial activity of cryptolepine and isocryptolepine, alkaloids isolated from *Cryptolepis sanguinolenta*. *Phytother Res* 1996;10:317-321.
12. Kirby GC, Paine A, Warhurst DC, Noamesi BK, Phillipson JD. In vitro and in vivo antimalarial activity of cryptolepine, a plant-derived indoloquinoline. *Phytother Res* 1995;9:359-363.
13. Noamesi BK, Paine A, Kirby GC, Warhurst DC, Phillipson JD. In vitro antimalarial activity of cryptolepine, an indoquinoline. *Trans Roy Soc Trop Med Hyg* 1991;85:315.
14. Ajayi AF, Akhigbe RE, Adewumi OM, Okeleji LO, Mujaidu KB, Olaleye SB. Effect of ethanolic extract of *Cryptolepis sanguinolenta* stem on in vivo and in vitro glucose absorption and transport: mechanism of its anti-diabetic activity. *Indian J Endocr Metab* 2012;16:S91-6.
15. Bierer DE, Fort DM, Mendez CD, Luo J, Imbach PA, Dubenko LG, Jolad SD, Gerber RE, Litvak J, Lu Q, Zhang P, Reed MJ, Waldeck N, Bruening RC, Noamesi BK, Hector RF, Carlson TJ, King SR. Ethnobotanical-directed discovery of the antihyperglycemic properties of cryptolepine: its isolation from *Cryptolepis sanguinolenta*, synthesis, and in vitro and in vivo activities. *J Med Chem* 1998;41:894-901.
16. Bierer DE, Dubenko LG, Zhang P, Lu Q, Imbach PA, Garofalo AW, Phuan PW, Fort J, Litvak DM, Gerber RE, Sloan B, Luo J, Cooper R, Reaven GM. Antihyperglycemic activities of cryptolepine analogues: an ethnobotanical lead structure isolated from *Cryptolepis sanguinolenta*. *J Med Chem* 1998;41:2754-64.
17. Luo J, Fort DM, Carlson TJ, Noamesi BK, Amon-Kotei D, King SR, Tsai J, Quan J, Hobensack C, Lapresca P, Waldeck N, Mendez CD, Jolad SD, Bierer DE, Reaven GM. *Cryptolepis sanguinolenta*: an ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycaemic agent. *Diabet Med* 1998;15:367-74.
18. Ansah Charles and Gooderham Nigel J. The popular herbal antimalarial, extract of *Cryptolepis sanguinolenta*, is potently cytotoxic. *Toxicol Sci* 2002;70:245-251.
19. Oyekan AO and Okafor JPO. Effects of cryptolepine alone and in combination with dipyridamole on a mouse model of arterial thrombosis. *J Ethnopharmacol* 1989;27:141-148.

20. Cimanga K, De Bruyne T, Pieters L, Vlietinck AJ, Turger CA. In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from *Cryptolepis sanguinolenta*. *J Nat Prod* 1997;60:688–691.
21. Paulo A, Duarte A, Gomes ET. In vitro antibacterial screening of *Cryptolepis sanguinolenta* alkaloids. *J Ethnopharmacol* 1994;44:127–130.
22. Silva O, Duarte A., Cabrita J, Pimentel M, Diniz A, Gomes E. Antimicrobial activity of Guinea-Bissau traditional remedies. *J Ethnopharmacol* 1996;50:55–59.
23. Boakye-Yiadom K, Herman Ackah SM. Cryptolepine hydrochloride: Effect on *Staphylococcus aureus*. *J Pharm Sci* 1979;68:1510–1514.
24. Cimanga K, De Bruyne T, Pieters L, Totte J, Tona L, Kambu K, Vanden Berghe D, Vlietinck AJ. Antibacterial and antifungal activities of neocryptolepine, biscryptolepine and cryptoquindoline, alkaloids isolated from *Cryptolepis sanguinolenta*. *Phytomed* 1998;5:209–214.
25. Paulo A, Pimentel M, Viegas S, Pires I, Duarte A, Cabrita J. *Cryptolepis sanguinolenta* activity against diarrhoeal bacteria. *J Ethnopharmacol* 1994b;44:73–77.
26. Sawyer IK, Berry MI, Brown MW, Ford JL. Antimicrobial activity of cryptolepine. *J Pharm Pharmacol* 1993;45:1108–1111.
27. Bamgbose SOA and Naomesi BK. Studies on cryptolepine II: Inhibition of carrageenan induced oedema by cryptolepine. *Planta Med* 1981;41:392-396.
28. Olajide OA, Ajayi AM, Wright CW. Anti-inflammatory properties of cryptolepine. *Phytother Res* 2009;23:1421-5.
29. Gellert E, Raymond-Hamet, Schlittler E. Die Konstitution des Alkaloids Cryptolepin. (The structure of the alkaloid cryptolepine) *Helv Chim Acta* 1951;34:642-51.
30. Paulo A, Gomes ET, Houghton PJ. New alkaloids from *Cryptolepis sanguinolenta*. *J Nat Prod* 1995;58:1485-91.
31. Tackie AN, Boye GL, Sharaf MHM. Cryptospirolepine, an unique spiro-nonacyclic alkaloid isolated from *Cryptolepis sanguinolenta*. *J Nat Prod* 1993;56:653-70.
32. Sharaf MHM, Schiff Jr. PL, Tackie AN, Phoebe Jr. CH, Martin GE. Two new indoloquinoline alkaloids from *Cryptolepis sanguinolenta*: cryptosanguinolentine and cryptotackieine. *J Heterocyclic Chem* 1996b;33:239-43.
33. Sharaf MHM, Schiff Jr. PL, Tackie AN, Phoebe Jr. CH, Johnson RL, Minick D. The isolation and structure determination of cryptomisine, a novel indolo [3,2-b] dimeric alkaloid from *Cryptolepis sanguinolenta*. *J Heterocyclic Chem* 1996a;33:789-97.
34. Pousset JL, Martin MT, Jossang A, Bodo B. Isocryptolepine from *Cryptolepis sanguinolenta*. *Phytochem* 1995;39:735-6.
35. Ansah C, Mfoafo EA, Woode E, Opoku-Okrah C and Owiredu WKBA. Toxicological evaluation of the anti-malarial herb *Cryptolepis sanguinolenta* in rodents *J Pharmacol Toxicol* 2008;3:335-343.
36. Akhigbe RE, Olatunji LA, Soladoye AO, and Oyeyipo IP. Effect of angiotensin 1-converting enzyme inhibitor, captopril, on body weight, and food and water consumption in oral contraceptive-treated rats. *Am J Biochem Mol Biol* 2011;1:95-100.
37. Yakubu MT, Akanji MA, Oladiji AT, Aphrodisiac potentials of aqueous extract of *Fadogia agrestis* (Schweinf. Ex Heirn) stem in male albino rats, *Asian J Androl* 2005;7:399-404.
38. Yakubu MT and Afolayan AJ. Effect of aqueous extract of *Bulbine natalensis* Baker stem on haematological and serum lipid profile of male Wistar rats. *Indian J Exp Biol* 2009;47: 283-288.
39. Saka WA, Akhigbe RE, Azeez OM, Babatunde TR. Effects of pyrethroid insecticide exposure on haematological and haemostatic profiles in rats. *Pak J Biol Sci* 2011;14:1024-1027.
40. Akhigbe RE, Azeez MO, Ige SF, Oyeyipo IP, Ajao FO and Soladoye AO. Hemorrhheological effect of long-term administration of oral contraceptive in rats. *Int J Pharmacol* 2008;4:403-406.
41. Saka WA, Akhigbe RE, Akinola AO, Azeez OM. Hemotoxicity of amodiaquine in Sprague-Dawley Rats. *Tox Int* 2012: In press
42. Dacie SIV, Lewis SM. Practical haematology 7th ed. Livingston, London, Melbourne and New York: J and A Churchill Ltd, 1991.
43. Joshi PK, Bose M, Harish D. Changes in certain haematological parameters in a siluroid catfish *Clarias batrachus* (Linn) exposed to cadmium chloride. *Pollution Resources* 2002; 22:129-131.
44. Eyong EU, Umoh IB, Ebong PE, Eteng MU, Antai AB, Akpa AO. Haematological effects following ingestion of Nigerian crude oil and crude oil polluted shellfish by rats. *Nigerian Journal of Physiological Sciences* 2004;19:1-6.
45. Oyedemi OS, Bradley G and Afolayan AJ. Toxicological effects of the aqueous stem bark extract of *Strychnos henningsii* Gig in Wistar rats. *J. Nat. Pharm* 2010;1:33-39.
46. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Deun KV, Smith P, Berger B and Heller A. Concordance of toxicity of pharmaceuticals in humans and in animals. *Reg Toxicol Pharmacol* 2000;32:56.
47. Sanchez-Elsner T, Ramirez JR., Rodriguez-Sanz F, Varela E, Bernabew C and Botella LMA. Cross talk between hypoxia and TGF-beta orchestrates erythropoietin gene regulation through SPI and smads. *J Mol Biol* 2004;36:9.
48. Adebayo JO, Adesokan AA, Olatunji LA, Buoro DO and Soladoye AO. Effect of Ethanolic extract of *Bougainvillea spectabilis* leaves on haematological and serum lipid variables in rats. *Biokemistri* 2005;17:45.
49. Klein J, Horej V. Immunology. Malden, MA: Blackwell Scientific, 1997.
50. Roitt I. Essential immunology. 9th ed. Malden, MA: Blackwell Scientific, 1997.
51. Janeway CA, Travers P, Walport M. Immunobiology: the immune system in health and disease. 4th ed. New York: Garland, 1999.
52. Patterson Roy, Greenberger Paul A., Grammer Leslie C. Patterson's Allergic Diseases. 6th edition. Lippincott Williams and Wilkins Publishers, 2002.

53. Williams N and Levine R F, The origin, development and regulation of megakaryocytes. *Br J Haematol* 1982;52:173.
54. Li J, Xia Y and Kuter D J. Interaction of thrombopoietin with the platelet complements receptor in plasma: binding, internalization, stability and pharmacokinetics. *Brit J Haematol* 1999;106:345.
55. Ganong W F. Review of Medical Physiology. 20th edition. Lange Medical Books/McGraw Hill Companies Inc., New York, 2001.
56. Grossmann A, Lenox J, Ren HP, Humes JM, Fortrom JW, Kaushansky K and Sprugel KH. Thrombopoietin accelerates platelet, red blood cell, and neutrophils' recovery in myelosuppressed rats. *Expt Hematol* 1996;24 :1238.

doi: <http://dx.doi.org/10.14194/ijmbr.119>

How to cite this article: Ajayi A.F, Akhigbe R.E, Adewumi O.M, Olaleye S.B. Haematological evaluation of *Cryptolepis sanguinolenta* stem ethanolic extract in rats. *Int J Med Biomed Res* 2012;1(1):56-61

Conflict of Interest: None declared